Autoantibodies in Autoimmune Disorders: Mechanisms of Pathogenesis, Diagnostic Utility, and Therapeutic Implications

Autoantibodies, once considered mere biomarkers of autoimmune disorders, are now recognized as central players in disease pathogenesis, offering critical insights into the breakdown of immune tolerance. This review synthesizes current knowledge on the dual roles of autoantibodies—as diagnostic tools and direct mediators of tissue damage—across a spectrum of autoimmune diseases. We begin by exploring the mechanisms underlying autoantibody production, including genetic predispositions (e.g., HLA haplotypes), environmental triggers (infections, microbiome dysbiosis), and dysregulated B-cell/T-cell interactions. Pathogenic mechanisms are dissected, from complement activation and immune complex deposition to receptor blockade/activation (e.g., anti-TSH receptor in Graves’ disease) and molecular mimicry. Highlighting disease-specific autoantibodies, we detail their clinical implications in systemic lupus erythematosus (anti-dsDNA, anti-Smith), rheumatoid arthritis (anti-CCP), and neurological disorders (anti-NMDA receptor, anti-AQP4). The review underscores the diagnostic and prognostic utility of autoantibodies, while addressing challenges such as seronegative autoimmunity and assay variability. Current therapeutic strategies, including B-cell depletion (rituximab), complement inhibition (eculizumab), and cytokine modulation, are evaluated alongside emerging approaches like antigen-specific tolerance induction and CAR-T cell therapy. Unresolved questions—such as why some autoantibodies remain asymptomatic and their role in disease initiation—are discussed, emphasizing the need for interdisciplinary research. Advances in single-cell technologies, proteomics, and AI-driven diagnostics promise to revolutionize personalized medicine, enabling early intervention and tailored therapies. By bridging mechanistic insights with clinical applications, this review underscores the transformative potential of autoantibody research in redefining autoimmune disease management and moving toward curative strategies.